Journal article icon

Journal article

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Abstract:

Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, but only ∼50% of patients respond. A response only manifests after many months of treatment and is transient. The reasons underlying AZA resistance are unknown, and few alternatives exist for non-res...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/j.celrep.2017.06.067

Authors


Unnikrishnan, A More by this author
Papaemmanuil, E More by this author
Deshpande, NP More by this author
Expand authors...
National Health and Medical Research Council More from this funder
Leukaemia Foundation More from this funder
Anthony Rothe Foundation More from this funder
Cancer Institute for New South Wales More from this funder
South Eastern Area Laboratory Services More from this funder
Expand funders...
Publisher:
Cell Press Publisher's website
Journal:
Cell Reports Journal website
Volume:
20
Issue:
3
Pages:
572-585
Publication date:
2017-07-18
DOI:
ISSN:
2211-1247
Pubs id:
pubs:709350
URN:
uri:3ff95b3b-7a63-40de-a9e5-c7ea6efd67e4
UUID:
uuid:3ff95b3b-7a63-40de-a9e5-c7ea6efd67e4
Local pid:
pubs:709350

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP